Shanghai Henlius Biotech, Inc. (2696) disclosed the completion of its H Share Full Circulation process. According to the announcement, 182,645,856 unlisted shares were successfully converted into H shares on February 4, 2026. Trading of these newly converted H shares is set to commence at 9:00 a.m. on February 5, 2026.

Following this conversion, the company’s share capital structure now comprises 197,420,456 unlisted shares (36.32% of the total issued shares) and 346,074,397 H shares (63.68% of the total issued shares). The total number of issued shares remains unchanged at 543,494,853.

Market participants are advised to exercise caution when trading the company’s securities and to refer to the official announcement for detailed information and context.